Letko, Brosseau & Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$32.1M |
| 2 |
Suncor Energy
SU
|
+$14.7M |
| 3 |
PROF
Profound Medical
PROF
|
+$14.6M |
| 4 |
Open Text
OTEX
|
+$10.1M |
| 5 |
GE Aerospace
GE
|
+$9.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Freeport-McMoran
FCX
|
+$39.2M |
| 2 |
Telus
TU
|
+$27.3M |
| 3 |
Hudbay
HBM
|
+$27.2M |
| 4 |
Verizon
VZ
|
+$25.5M |
| 5 |
Magna International
MGA
|
+$24.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 28.93% |
| 2 | Communication Services | 16.1% |
| 3 | Materials | 12.96% |
| 4 | Energy | 12.54% |
| 5 | Technology | 7.42% |
Similar funds
Letko, Brosseau & Associates's Q4 2020 Portfolio in Review
As of Q4 2020, Letko, Brosseau & Associates held 108 positions worth $7.3B, up 14% from $6.43B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Letko, Brosseau & Associates withdrew a net $617M in Q4 2020, closing 2 positions and reducing 71 holdings. Its most notable exit was TFI International, an estimated $390K position sold in full.
By sector, the portfolio is most concentrated in Financials at 29% of assets, up from 29% a quarter earlier, followed by Communication Services and Materials.
Against the trend, Letko, Brosseau & Associates opened a new position in CVS Health worth $33.7M.
- Letko, Brosseau & Associates's largest Q4 2020 buy was CVS Health: 492,850 shares worth $33.7M.
- Letko, Brosseau & Associates added most to Suncor Energy in Q4 2020, an estimated $14.7M increase.
- Letko, Brosseau & Associates's biggest Q4 2020 reduction was Freeport-McMoran, cutting an estimated $39.2M.
- Letko, Brosseau & Associates fully exited TFI International in Q4 2020, selling an estimated $390K.
- Letko, Brosseau & Associates's ten largest holdings make up 36% of its $7.3B portfolio in Q4 2020.
- Letko, Brosseau & Associates opened 11 new positions and closed 2 in Q4 2020.
- Letko, Brosseau & Associates's portfolio value rose 14% quarter-over-quarter to $7.3B.
Based on Letko, Brosseau & Associates's 13F filing for Q4 2020, filed 5 Feb 2021.